Milestone Pharmaceuticals (MIST) announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA, seeking the approval of etripamil nasal spray, developed to be the first rapid, reliable option in the treatment of paroxysmal supraventricular tachycardia, PSVT, outside of the healthcare setting. Etripamil, which has the conditionally approved brand name TACHYMIST in Europe, is an investigational, novel calcium channel blocker delivered via a nasal spray by the patient for the potential treatment of PSVT and other cardiac arrhythmias. A decision on approval is expected by the first quarter of 2027.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo
- Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval
- Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen
- Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential
- Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright